Evidence map›Paper›PMID 38163666›Full record

ArticleJournal of Zhejiang University. Science. B2024

Mass spectrometry analysis of intact protein

Mingming Xu, Zhaoliang Liu, Wenhua Hu, Ying Han, Zhen Wu, Sufeng Chen, Peng Xia, Jing DU, Xumin Zhang, Piliang Hao and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Zhejiang University. Science. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Mingming XuCenter for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Zhaoliang LiuCenter for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Wenhua HuCenter for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
Ying HanSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Zhen WuState Key Laboratory of Genetic Engineering, Department of Biochemistry, School of Life Sciences, Fudan University, Shanghai 200438, China.
Sufeng ChenDepartment of Clinical Laboratory Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.
Peng XiaDepartment of Clinical Laboratory Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.
Jing DUDepartment of Clinical Laboratory Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China.
Xumin ZhangState Key Laboratory of Genetic Engineering, Department of Biochemistry, School of Life Sciences, Fudan University, Shanghai 200438, China.
Piliang HaoSchool of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
Jun XiaDepartment of Clinical Laboratory Center, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China. yangs2020@suda.edu.cn, andisky_005@126.com.
Shuang YangCenter for Clinical Mass Spectrometry, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China. yangs2020@suda.edu.cn.
Soochow University · CNZhejiang Provincial People's Hospital · CNFudan University · CNShanghaiTech University · CN

Funding

the Foundation of Zhejiang Provincial Administration of Traditional Chinese Medicine 2020ZB020the Jiangsu Shuangchuang Boshi Funding JSSCBS20210697the Soochow University Start-up Fund, the Priority Academic Program Development of the Jiangsu Higher Education Institutes (PAPD), the Jiangsu Science and Technology Plan Funding BX2022023
6 · The paper itself

Abstract

Pancreatic cancer is among the most malignant cancers, and thus early intervention is the key to better survival outcomes. However, no methods have been derived that can reliably identify early precursors of development into malignancy. Therefore, it is urgent to discover early molecular changes during pancreatic tumorigenesis. As aberrant glycosylation is closely associated with cancer progression, numerous efforts have been made to mine glycosylation changes as biomarkers for diagnosis; however, detailed glycoproteomic information, especially site-specific

Indexed as

AdenocarcinomaPancreatic NeoplasmsBiomarkersGlycoproteinsGlycosylationHumansMass SpectrometryPolysaccharidesProto-Oncogene Proteins p21(ras)BiomarkersGlycoproteinsPolysaccharidesProto-Oncogene Proteins p21(ras)BiomarkerGlycoproteomicsGlycosylationMass spectrometryPancreatic cancer

Identifiers

PMID38163666
PMCPMC10758206
OpenAlexW4390507440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.